Abstract
A diverse repertoire of T cells directed against a small number of cancer-specific targets is key to the success of immune checkpoint blockade in patients with metastatic melanoma, a finding that could shape the design of neoantigen-specific vaccines and adoptive cell therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
